Interleukin IL-22, a new target to inhibit the progression of liver disease

(University of Montreal Hospital Research Centre (CRCHUM)) Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease. They have characterized the mechanisms of action of type 3 inflammatory cytokines that are produced by the cells of the immune system, which result in a progression of hepatic scarring known as fibrosis. These research efforts have identified new potential targets to inhibit the progression of liver disease and prevent cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news